Drug Discovery and Development

Symbol of rare disease, realistic pink, green, blue ribbon. Template for awareness day on 28 february isolated over white background, vector illustration.

The FDA plans its third rare disease policy change in just over a year

AAPS names Patrick Sinko chief science officer

Researchers studying a purple microscopy image of cells on a large screen, digital pathology and histology analysis in bright lab.

Digital pathology’s next act: Mining old tissue to spare future animal studies

AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists

Red Tariffs label on a hundred dollar bill

Pharma tariffs reach smaller drugmakers as industry warns of R&D pressure

‘A plate of spaghetti’: Talus Bio boasts 5,000-fold faster drug screening by skipping protein folding

Alphabet and Meta now spend nearly as much on R&D as pharma’s 10 largest drugmakers

Pharma commercial vendor selection still runs on word of mouth. A Harvard MBA student aims to change that with Rx Almanac.

Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment

After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice 

The 50 largest pharmaceutical companies in the world
50 of the best-selling pharmaceuticals
Pharma 50 Deep Dive: Keytruda holds the top brand slot

Today on Drug Discovery & Development

By |

The FDA plans its third rare disease policy change in just over a year

On Oct. 14, the FDA announced a plan called the “Rare Disease Framework Initiative,” described in a new white paper, to build a “fit-for-purpose” approach to reviewing drugs and biologics for rare diseases. The FDA says the initiative aims to give developers of rare disease treatments clearer, more consistent guidance on the evidence needed for…

By |

AAPS names Patrick Sinko chief science officer

The American Association of Pharmaceutical Scientists (AAPS) has named Patrick J. Sinko, Ph.D., R.Ph., as chief science officer. Sinko will set the organization’s scientific strategy, guide scientific programming across in-person and digital platforms, and guide the direction of AAPS’s portfolio of peer-reviewed journals. Sinko, a pharmacist and pharmaceutical scientist, retains his academic appointment at Rutgers,…

By |

Digital pathology’s next act: Mining old tissue to spare future animal studies

The field of digital pathology went from a specialist interest to a practical necessity during the pandemic, when many pathologists couldn’t get to the microscope. Digitizing slides let them keep working remotely. Since then, researchers have developed ways to extract more information from those images, including patterns linked to molecular changes in tissue. Traditionally, the…

Read All Articles >

Drug Discovery and Development See More >

2026 PharmSci 360 adds tracks on research credibility and post-animal drug development

The Arlington, Virginia–based nonprofit American Association of Pharmaceutical Scientists (AAPS) will launch two Innovator-Curated tracks at its 2026 PharmSci 360 conference, scheduled for October 25–28, 2026, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The organization announced that the tracks will explore the current state of scientific research integrity in an AI…

Sponsored Content See More >

Accelerating life sciences with AI
 This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…

Genomics/Proteomics See More >

New cell imaging method reveals hidden enzyme activity 

Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…

Infectious Disease See More >

Cancer vaccine borrows COVID immune memory to activate T cells against tumors in mice 

The COVID-19 pandemic left most of the world’s population with an immune memory for COVID. A Cleveland-based biotech wants to use that memory to fight cancer. Celloram, a preclinical stage company focusing on therapies for cancer, autoimmune diseases and chronic inflammatory and metabolic disorders, in partnership with Case Western Reserve University and University Hospitals Cleveland Medical Center, published preclinical results for a…

Oncology See More >

Measuring Psilocybin Magic Mushroom Micro Doses in Laboratory for A Scientific Experiment

After decades of trial failures in chemotherapy-linked neuropathy, psilocybin shows promise in preventing it in mice 

The magic mushroom compound psilocybin, which has had favorable results in two Phase 3 trials of depression and could be available as soon as 2027, has shown promise in rodents as a potential preventative for Chemotherapy‑Induced Peripheral Neuropathy (CIPN), a disabling pain condition caused by chemotherapy that affects about 30% to 50% of patients receiving chemotherapy. A 2014 review found that 68.1% of chemotherapy patients across 31 studies had CIPN when measured in…

Search Drug Discovery & Development